Blood Sample Processing for UCH-L1 Biomarker Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing traumatic brain injury (TBI) using biomarkers like ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) are hindered by preanalytical errors, such as incorrect sampling times, hemolysis, and improper handling of blood samples, leading to inaccurate measurements and false positives.
Innovation Solution
Processing blood samples within eight hours or less after collection, using anticoagulants like heparin or EDTA, and avoiding mechanical agitation and temperature extremes to stabilize UCH-L1 levels, followed by separation of plasma or serum for accurate assays using methods like centrifugation or chromatography.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of time
If blood samples are stored for extended periods before processing, then logistical flexibility is improved, but UCH-L1 levels increase erroneously leading to false positives
Solution Approach 1:
The patent applies preliminary action by adding protease inhibitors to the blood collection tube at the time of sampling, before any storage occurs. This pre-protection prevents UCH-L1 degradation and artifactual increase during storage, allowing samples to be processed within 8 hours without compromising accuracy. The protease inhibitor is already present in the tube, so no additional action is needed during storage or processing.
2Ease of operation
If standard blood collection procedures are used without special handling, then ease of collection is maintained, but preanalytical errors such as hemolysis and improper handling occur
Solution Approach 1:
The patent introduces protease inhibitors as an intermediary substance in the blood collection tube that mediates between the standard collection procedure and sample quality preservation. These inhibitors act as a protective intermediary that prevents degradation and artifactual changes without requiring changes to the collection technique itself, thus maintaining ease of operation while improving reliability.
3Adaptability or versatility
If UCH-L1 levels are measured without controlling storage conditions, then workflow flexibility is improved, but measurement accuracy deteriorates due to time-dependent level changes
Solution Approach 1:
The patent applies preliminary action by pre-equipping collection tubes with protease inhibitors and providing clear labeling indicating the 8-hour processing window. This allows laboratories to maintain workflow flexibility and process samples at varying times within the window without compromising accuracy, as the protective mechanism is already in place before storage begins.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach reduces preanalytical errors, stabilizes UCH-L1 levels, and enhances the accuracy of TBI diagnosis by minimizing erroneous increases in UCH-L1 levels, thereby improving the reliability of TBI assessments.
Implementation Method 1
separation of plasma or serum for accurate assays using methods like centrifugation or chromatography
Implementation Method 2
using anticoagulants like heparin or EDTA, and avoiding mechanical agitation and temperature extremes to stabilize UCH-L1 levels
Data Source
AI summary
Disclosed herein are improved methods of processing, measuring, and detecting levels of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) in blood samples taken from a human subject at time points within about 8 hours (or about 8 hours or less) after obtaining the sample from the subject. UCH-L1 is an early biomarker for traumatic brain injury (TBI), and there is a need for improved methods for assessing UCH-L1 in blood can aid in the diagnosis and evaluation of a human subject who has sustained or may have sustained a head injury.